Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel Oncolytic Virus in Late Stage Solid Tumors
NCT06080984Phase 1Unknown
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of SDJ001 and YD06-1 in head and neck squamous cell carcinoma (HNSCC), melanoma and soft tissue sarcoma (STS), sponsored by West China Hospital of Sichuan University. Primary endpoint: Adverse events up to 12 months. Status: unknown.
02
Drugs
SDJ001YD06-1
03
Conditions
head and neck squamous cell carcinoma (HNSCC)melanomasoft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06080984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06080984.